Background: The role of IGF-I in prostate development is currently under thorough investigation since it has been claimed that IGF-I is a positive predictor of prostate cancer. Objective: To investigate the effect of chronic GH and IGF-I de®ciency alone or associated with testosterone de®ciency on prostate pathophysiology in a series of patients with hypopituitarism. Design: Pituitary, androgen and prostate hormonal assessments and transrectal prostate ultrasonography (TRUS) were performed in 30 men with adulthood onset GH de®ciency (GHD) and 30 agematched healthy controls, free from previous or concomitant prostate disorders. Results: Plasma IGF-I levels were signi®cantly lower in GHD patients than in controls (Pearson's coef®cient P < 0.0001). At study entry, 6 of the 13 hypogonadal patients and 7 of the 17 eugonadal patients had plasma IGF-I below the age-adjusted normal range. At study entry, testosterone levels were low in 13 patients (mean 6 S.E.M., 3.8 6 1.0 nmol/l) while they were normal in the remaining 17 (19.4 6 1.4 nmol/l). No difference in prostate-speci®c antigen (PSA), and PSA density was found between GHD patients (either hypo-or eugonadal) and controls, while free PSA levels were signi®cantly higher in eugonadal GHD than in controls (0.4 6 0.04 vs 0.2 6 0.03 mg/l; P < 0.01).
Introduction
Testosterone and its more potent 5-a-reduced metabolite, dihydrotestosterone (DHT) are the most important determinants of physiological development and growth of the prostate (1) . In particular, DHT is considered as the leading factor in stimulating prostate benign and malignant disorders (1) , although occult prostate carcinoma has been found also in patients with low testosterone levels (2) . However, great attention has been recently given to the role played by insulin-like growth factors (IGFs)-I and -II and IGF-binding proteins (IGFBPs) on the prostate (3). Both IGFs possess direct mitogenic effects on several tissues, including normal and tumoral prostate epithelial cells and their implication in prostate cancer has been suggested as well (4±6). Moreover, IGF-I was found to be directly correlated while IGFBP-3 resulted inversely correlated to prostate cancer risk (5) . Changes in each of the IGF-I system, IGFs and their receptors, IGFBPs and IGFBP proteases, have been reported in prostate cancer (7) . Although normal prostatic epithelial cells, which are the cells originating prostate cancer, neither synthesize nor secrete signi®cant amounts of IGF-I or IGF-II, they respond to the mitogenic stimulation of IGFs (8) . IGF-I seems to be implicated in promoting overgrowth of the prostate: speci®c binding sites for IGF-I are present in prostatic tissue from patients with benign prostatic hyperplasia (BPH), and androgen deprivation by gonadotropin-releasing hormone analogue treatment increases their binding capacities and seems to modify IGF-I receptors localization in the prostatic epithelium (9) . The hypertrophic effect of IGF-I on the prostate has also been recently observed in acromegalic patients (10, 11) . Prostate hypertrophy and increased prevalence of prostate abnormalities were found in acromegalic patients as compared with age-matched controls even in younger ones not expected to have agedependent prostate diseases (10, 11) . Suppression of circulating growth hormone (GH) and IGF-I after treatment with octreotide induced a signi®cant reduction of prostate volume, suggesting a direct relationship between the GH±IGF-I axis and prostate size (10) .
No data are presently available on prostate size and disease in adult patients with GH de®ciency (GHD). GHD in adults is a complex syndrome as it is associated with changes in bone turnover and body composition, impairment in lipid pro®le, reduction in exercise capacity and abnormalities in cardiac function (12, 13) . Whether in childhood GHD has a different pathophysiology, in adulthood it is due to a pituitary tumor in the large majority of cases (14) . In adult GHD patients, therefore, some degree of pituitary insuf®-ciency occurs together with GHD, and combined folliclestimulating hormone (FSH) and luteinizing hormone (LH) de®ciency causing hypogonadism is a rather frequent event (15) .
This open transversal study was designed in order to investigate prostate volume and structural impairment, by means of transrectal ultrasonography (TRUS), pituitary, androgen and prostate hormones concentrations in adult patients who acquired GHD in adulthood. The impact of combined testosterone and GH de®ciency was also investigated.
Subjects and methods

Subjects
Thirty men, aged 22±72 years (54.3 6 2.5 years, mean 6 S.E.M.) with pituitary tumors and 30 healthy men aged 26±74 years (52.9 6 2.3 years) were enrolled in this study, free of previous or present prostate diseases and not under replacement treatment with a-adrenergic antagonists or anti-androgen drugs. None of them had previously experienced any episode suggesting prostate and/or urethral disorders, such as prostatitis, orchitis, in¯ammation of seminal vesicles, spontaneous or precipitated acute urinary retention. The study was performed after approval of local Ethical Committee. All patients and controls gave their informed consent to participate in the study. All subjects were tested with the combined arginine (ARG) plus GH-releasing hormone (GHRH) test (ARG+GHRH). According to recent studies (16±18), a GH response to ARG+GHRH below 9 mg/l is considered diagnostic of GHD. Among the 30 patients, 23 were diagnosed to have a very severe GHD (GH peak <3 mg/l) while seven other patients had a severe GHD (GH peak 3.1±9 mg/l) (16±18). Table 1 shows anthropometric and endocrine data of the 30 GHD patients at study entry. All patients, but one with a macroprolactinoma only treated with cabergoline (no. 10, Table 1 ), had been previously operated on via trans-sphenoidal and/or trans-cranic route for GH-secreting, prolactin (PRL)-secreting, non-functioning pituitary adenoma or craniopharyngioma and eight of them had been irradiated. Twenty patients had panhypopituitarism, seven patients had FSH/LH and TSH de®ciency, and three patients had GHD alone. Hormone replacement therapy with L-thyroxine (50±100 mg p.o. daily), cortisone acetate (25±37.5 mg/day), was given where appropriate. Thirteen patients with hypogonadism were treated with testosterone enanthate (250 mg i.m. monthly) for 0.5±10 years prior to entering the study, 13 patients had hypogonadism at study entry while the remaining four had normal testosterone levels ( Table 1) . Adequacy of hormone replacement therapy was periodically assessed by serum-free thyroid hormones, testosterone, urinary-free cortisol and serum and urinary Na + and K + measurements. None of the patients had ever received GH treatment. In patients receiving testosterone replacement, hormone levels were assessed within 1 week before the next injection. In order to avoid overestimation, the duration of the disease was calculated from the time of diagnosis and the retrospective evaluation of symptoms presumably related to the pituitary disease was not considered. In this group the average disease duration was 7.3 6 1.1 years.
Seven GHD patients and eight controls were mild smokers; none in either of the two groups was a heavy alcohol drinker and all had a normal diet intake.
Study design
The study protocol included hormonal tests performed by using commercially available kits, and subsequently prostate TRUS. ARG (arginine hydrochloride, Damor, Naples, Italy) was administered at the dose of 0.5 g/kg, up to a maximal dose of 30 g slowly infused from time 0 to 30 min while GHRH (1±44), (Serono, Rome, Italy) was given at the dose of 1 mg/kg as i.v. bolus at 0 min (17, 18) . Blood samples were taken every 15 min from ± 15 up to 90 min. Circulating IGF-I, PRL, FSH, LH, testosterone, DHT, prostate-speci®c antigen (PSA), free PSA and prostate alkaline phosphetase (PAP) levels were assessed at least twice. In this study, the average value of the two assays was shown. The cut-off value of 4 mg/l was considered as the upper limit for PSA concentrations. The calculation of PSA density, expressed as the ratio of PSA levels/prostate volume was considered as a risk factor for prostate cancer when higher than 0.15. All assessments were age-adjusted. Serum GH levels were measured by IRMA using commercially available kits (HGH-CTK-IRMA Sorin, Saluggia, Italy). The sensitivity of the assay was 0.2 mg/l. The intra-and inter-assay coef®cients of variation (CV) were 4.5 and 7.9% respectively. Plasma IGF-I was measured by IRMA after ethanol extraction. The sensitivity of the assay was 0.8 mg/l. The normal IGF-I range in our laboratory was 100±502, 100±303 and 78±258 mg/l for patients aged 20±40, 41±60 and over 60 years respectively. The intra-assay CV were 3.4, 3.0 and 1.5% for low, medium and high points on the standard curve respectively. The inter-assay CVs were 8.2, 1.5 and 3.7% for low, medium and high points on the standard curve respectively. Plasma IGFBP-3 was measured by RIA after ethanol extraction. The sensitivity of the assay was 0.5 mg/l. The intra-assay CVs were 3.9, 3.2 and 1.8% for low, medium and high points on the standard curve respectively. The inter-assay CVs were 0.6, 0.5 and 1.9% for low, medium and high points on the standard curve respectively. The normal IGFBP-3 range in our laboratory for 20±40, 41±60 and over 60-year-old subjects was 2.7±7.2, 2.0±4.3 and 2±4 mg/l respectively. The kits for IGF-I and IGFBP-3 assay were purchased from Diagnostic System Laboratories Inc.
(Webster, TX, USA).
Transrectal ultrasonography study
Before TRUS, all 44 subjects received a preliminary enema with 200 ml of Sorbitole and a digital rectal exploration. TRUS was performed by means of an Esaote AU5 harmonic EPI and a 5±6-7.5 MHz biconvex (Esaote, Genoa, Italy) transrectal transducer with Power Echo color Doppler (PECD) module to display prostate angiographic micromaps (19, 20) . The transducer, preliminarily covered with ultrasound transmission gel (Acquasonic, Parker Lab., NJ, USA) and a disposable rubber sheath, was lubricated and gradually inserted about 3 cm into the rectum, then directed towards the anterior rectal wall. The prostate examination covered the antero-posterior (APD), transversal (TD) and cranio-caudal (CCD) diameters; the transitional zone; the morphology of boundaries; the occurrence of calci®cations and nodules; the evaluation of seminal vesicles and of in¯ammatory events not previously reported by the patients. The volume of the prostate (PV) and of the transitional zone (TZV) was calculated by means of the standard ellipsoid formula (0.52´APD´TD´CCD). Echo-guided prostate biopsies with power Doppler enhancement were performed if clinical or hormonal conditions required it. All scans were performed by the same investigator (SS), blind in respect to subject examinations. Prostate hyperplasia (PH) was considered for PV exceeding 30 ml, in line with the accepted criteria for BPH (21, 22) . 
Statistical analysis
Results
Hormonal data
Individual data of GHD patients are shown in Table 1 while the comparison between GHD patients and controls is shown in Table 2 . Compared with controls, GH peak after ARG+GHRH (P < 0.0001), IGF-I (P < 0.0001) and IGFBP-3 (P < 0.0001) levels were signi®cantly reduced in GHD patients (Table 2) . Testosterone and DHT levels were below the normal range in 13 and 10 patients respectively, while they were normal in the remaining 17 patients (Table 1) . No difference was found in disease duration between eugonadal and hypogonadal GHD patients ( Table 2) . At study entry, plasma IGF-I levels were below the ageadjusted normal range in 6 of the 13 hypogonadal patients and 7 of the 17 eugonadal patients (Table 1) .
No difference in PSA levels and PSA density was found between GHD patients, either eugonadal or hypogonadal, and controls (Tables 1 and 2 ). Plasma f-PSA levels were signi®cantly higher in eugonadal GHD patients (0.4 6 0.04 mg/l) than in controls (0.2 6 0.03 mg/l, P < 0.01). High PSA, free-PSA (f-PSA) and PSA density levels were found in 2, 20 and 7 patients respectively (Table 1) . Eight controls had elevated f-PSA levels (data not shown).
Prostate dimensions (Table 2)
No difference was found by TRUS in APD and TZV among groups, while in hypogonadal and eugonadal GHD patients both TD and CCD, and consequently PV, were signi®cantly reduced compared with controls (Table 2) . PH (>30 ml) was found in 13 controls (43.3%), two hypogonadal (15.3%) and three eugonadal GHD patients (5.8%) (Fig. 1) , thus the prevalence of PH was signi®cantly lower in hypogonadal and eugonadal GHD patients than in controls (x 2 6.90, P 0:005). The transitional zone was not detectable in three GHD, two hypo-and one eugonadal, patients and in four controls. When prostate dimensions were analyzed considering the presence or absence of IGF-I de®ciency, no difference in APD, TD, CCD, TZV or PV was found between patients with normal or de®cient IGF-I levels both in the hypogonadal group and in the eugonadal group (Fig. 2) . In contrast, when prostate dimensions were analyzed in line with age below or above 60 years, young (aged below 60 years) hypogonadal GHD patients had the lowest PV and TZV levels while no difference was found between controls and eugonadal GHD patients (Fig. 3) . In addition, a signi®cantly higher PV, but not TZV, was found in elderly controls (aged above 60 years) than in age-matched hypogonadal and eugonadal GHD patients, without any difference between them (Fig. 3) . In addition, f-PSA levels were signi®cantly lower in young controls than age-matched hypogonadal and eugonadal GHD patients (0.15 6 0.02 vs 0.33 6 0.09 and 0.44 6 0.04 mg/l, P < 0.05 and <0.001 respectively), and PSA density was signi®cantly higher in young hypogonadal GHD patients than in age-matched controls and eugonadal GHD patients (0:11 6 0:03 vs 0.06 6 0.006 and 0.06 6 0.006, P < 0.05). No difference was found in PSA levels between young and elderly subjects among groups, and in f-PSA levels and PSA density in elderly subjects among groups.
Prostate features
No abnormality of prostate structure was detected in 13 patients (43.3%) and in 15 controls (50%).
Calci®cations were detected in 15 GHD patients (50%) (®ve hypo-and ten eugonadal), and eight controls (26.6%) (x 2 4.74, P = 0.09). Cysts were found in six patients (20%), (two hypo-and four eugonadal) and four controls (13.3%) (x 2 0.83, P 0:7). Echoic signs suggesting a condition of vesicles in¯ammation, were observed in three eugonadal patients (10%) and no controls, while a prostate nodule was detected in one hypogonadal patient (no. 10, Table 1 ). At echo-guided needle aspiration cytological examination, nodular ®bro-adenomatous hyperplasia was found. Sextant biopsies of the prostate were performed in six other patients due to elevation of PSA levels and/or PSA GH de®ciency and prostate growth 65 EUROPEAN JOURNAL OF ENDOCRINOLOGY (2000) 143 www.eje.org Table 2 Endocrine and ultrasonographic ®ndings (expressed as mean 6 S.E.M.) in control subjects and in hypogonadal and eugonadal GHD patients.
GHD patients
Controls
Hypogonadal Eugonadal (n 30) (n 13) (n density. Prostate cancer was found in none of them. The prevalence of structural prostate abnormalities, such as calci®cations, cysts and nodules, was similar in patients (56.7%) and controls (50%) (x 2 0.067, P 0.79).
Correlation analysis
The results of the correlation analysis are shown in Table 3 . Both in controls and in GHD patients, PV and TZV were correlated to each other (r 65, P < 0.0001 66 A Colao and others
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www.eje.org Figure 2 Prostate transversal diameter (top), cranio-caudal diameter (middle) and volume (bottom) in controls, hypogonadal and eugonadal GHD patients grouped in line with normal or de®cient IGF-I levels. Error bars represent means 6 S.E.M. *Signi®cant P < 0:01 vs controls. Figure 3 Serum IGF-I levels (top), prostate volume (middle) and transitional zone (TZ) volume (bottom) in controls, hypogonadal and eugonadal GHD patients subdivided in line with age. Error bars represent means 6 S.E.M. *Signi®cant P < 0:005 vs agematched hypogonadal and eugonadal GHD patients; **signi®cant P < 0:01 vs age-matched hypogonadal GHD patients; ***signi®cant P < 0:05 vs age-matched controls and eugonadal GHD patients.
and r 0.52, P 0.003 respectively). At the multistep analysis, in control subjects age was the strongest predictor of PV (t 7.658, P < 0.001), while PSA and DHT levels were the strongest predictors of TZV (t 7.234, P < 0.001 and t 3.535, P 0.002 respectively). In GHD patients, the GH peak after ARG GHRH was the strongest predictor of PV (t 2.525, P 0.018), and PSA levels were the strongest predictors of TZV (t 3.876, P 0.001).
Discussion
The results of this study demonstrate that PV was signi®cantly decreased both in hypogonadal and eugonadal GHD adult patients, without any difference between them, accounting for a reduced prevalence of PH in GHD patients than in controls. Conversely, the prevalence of structural prostate abnormalities was similar in GHD patients, either hypogonadal or eugonadal, and controls. Androgen deprivation, by castration or pharmacotherapy, notoriously causes impairment of prostate growth (1) . Androgen level seems also to modify the number, but not the af®nity, of IGF-I receptors on prostate epithelium. In fact, an increase in the number of IGF-I type I receptors was demonstrated in cell cultures from patients with BPH after testicular suppression by gonadotropin-releasing hormone (GnRH) analogues (9) . Moreover, whether prior to GnRH analogue treatment IGF-I type I receptors were found in the basal layer of prostatic epithelium, during androgen deprivation these receptors appeared also in the secretory cells, which are preferentially damaged by castration (23) . Evidence is accumulating that IGFs are involved in prostate cell proliferation (24) : IGF-I acts as mitogen on primary cultures of prostatic cells (25) , prostatic epithelial cells produce IGFBPs (26) , found also in tissues from patients with BPH (25) . Whether chronic GH and/or IGF-I de®ciency plays any role on prostate size and structure is still unknown.
In order to investigate the role played by GH and IGF-I on prostate growth and disease we designed this study enrolling adult patients with hypopituitarism. In the majority of adult patients with GHD, other pituitary hormone de®ciency may occur, being FSH and LH de®ciency the most frequently associated hormone defect (14, 15) . As testosterone and DHT are the main stimulator factors of prostate growth and disease, GHD patients were studied separately in line with presence or absence of concomitant hypogonadism. A signi®cant decrease in PV was observed in patients with GHD, mostly in those with combined GH and testosterone de®ciency, but a slight signi®cant decrease in PV was also observed in patients with normal androgen levels at the time of the study. It should be considered that the majority of the patients included in the eugonadal GHD group were under testosterone replacement, and the possibility that the hypogonadism they had suffered from for several years could have affected prostate size is highly likely. On the other hand, no difference in PV was found between controls and eugonadal GHD patients aged below 60 years, who had signi®cantly higher volumes of both the entire prostate and the transitional zone than young hypogonadal GHD patients. Elderly controls had signi®cantly higher PV, but not TZV, than both hypogonadal and eugonadal GHD patients, indicating that a prolonged state of GH and/or IGF-I de®ciency either or not combined with androgen de®ciency is necessary before a reduction in prostate size can be documented. The results of prostate size, but not structure, in GHD patients paralleled the known decrease in other organs such as the heart (27) . However, no difference in the abnormalities of prostate structure was found between controls and patients, being calci®cations detected in 26.6% and 50%; cysts in 13.3% and 20%, vesicles impairment and/or benign nodules were found in 13.3% of patients and none of controls. A trend to an increased prevalence of calci®cations was observed in eugonadal GHD patients (58.8%) either when compared with hypogonadal GHD patients (34.8%) and to controls (26.6%), although it did not attain statistical signi®cance. Whether this could be due to androgen replacement can not be ruled out. IGFBP-2 and IGFBP-3, circulating carriers of IGF-I, can be cleaved by the PSA contained in the seminal plasma, so increasing the intra-prostatic concentration of IGF-I (28), and, as shown by in vitro studies, prostate cell growth is stimulated by IGF-I and inhibited by IGFBP-3 (3, 29±31). However, no signi®cant difference in IGFBP-3 levels was found between hypogonadal and eugonadal patients and in both GHD groups IGFBP-3 levels were signi®cantly lower than in controls. Although the model of GHD in humans is perhaps not the best method to investigate in vivo the effect of the GH/IGF-I axis on the prostate as in these patients both IGF-I and IGFBP-3 are low, no difference was found in prostate volume and diameters between patients with normal or abnormally low IGF-I levels. It should be noted, however, that even patients with normal IGF-I levels had their values in the low to normal range. However, in our controls a strong inverse correlation was found between IGF-I and IGFBP-3 levels and PV.
In conclusion, the results of the present study show that longstanding GH and/or IGF-I de®ciency induced a decrease in prostate size mostly in patients with concomitant testosterone de®ciency. It is intriguing that in contrast with acromegaly, where prostate volume increased with aging even with low androgens levels, in GHD patients prostate volume did not correlate with age, as in controls, even in presence of normal androgen levels.
